Methotrexate has been used in treatment of rheumatoid arthritis (RA) since the 1980s and to
this day is often the first line medication for RA treatment. In this review, we examine multiple …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …

Biological molecules are increasingly becoming a part of the therapeutics portfolio that has
been either recently approved for marketing or those that are in the pipeline of several …

Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the
gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of …

The availability of monoclonal antibodies has revolutionized the treatment of an increasingly
broad spectrum of diseases. Inflammatory diseases are among those most widely treated …

Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the
development and approval of the first biological disease-modifying antirheumatic drugs …

With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering
the clinic, recent data highlight immunogenicity as an emerging challenge in the …

The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because
they have dramatic efficacy. At the same time, safety concerns about biologics have been …

MTX is an immunosuppressant drug that occupies a key place in the management of many
autoimmune and inflammatory skin diseases. Although MTX has been widely prescribed in …